These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 17580184)

  • 1. Blood eosinophilia after living donor liver transplantation for hepatitis C virus-related cirrhosis.
    Kishi Y; Sugawara Y; Kaneko J; Tamura S; Matsui Y; Makuuchi M
    Transplant Proc; 2007 Jun; 39(5):1540-3. PubMed ID: 17580184
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Is blood eosinophilia an effective predictor of acute rejection in living donor liver transplantation?
    Kishi Y; Sugawara Y; Tamura S; Kaneko J; Akamatsu N; Togashi J; Makuuchi M
    Transpl Int; 2005 Oct; 18(10):1147-51. PubMed ID: 16162101
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunohistochemical staining of liver grafts with a monoclonal antibody against HCV-Envelope 2 for recurrent hepatitis C after living donor liver transplantation.
    Sadamori H; Yagi T; Iwagaki H; Matsuda H; Shinoura S; Umeda Y; Ohara N; Yanai H; Ogino T; Tanaka N
    J Gastroenterol Hepatol; 2009 Apr; 24(4):574-80. PubMed ID: 19368635
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Histologic eosinophilia as an aid to diagnose acute cellular rejection after living donor liver transplantation.
    Kishi Y; Sugawara Y; Tamura S; Kaneko J; Matsui Y; Makuuchi M
    Clin Transplant; 2007; 21(2):214-8. PubMed ID: 17425747
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Assessment of graft fibrosis by transient elastography in patients with recurrent hepatitis C after living donor liver transplantation.
    Harada N; Soejima Y; Taketomi A; Yoshizumi T; Ikegami T; Yamashita Y; Itoh S; Kuroda Y; Maehara Y
    Transplantation; 2008 Jan; 85(1):69-74. PubMed ID: 18192914
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differential transcriptome patterns for acute cellular rejection in recipients with recurrent hepatitis C after liver transplantation.
    Asaoka T; Kato T; Marubashi S; Dono K; Hama N; Takahashi H; Kobayashi S; Takeda Y; Takemasa I; Nagano H; Yoshida H; Ruiz P; Tzakis AG; Matsubara K; Monden M; Doki Y; Mori M
    Liver Transpl; 2009 Dec; 15(12):1738-49. PubMed ID: 19938108
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prediction of acute cellular rejection by peripheral blood eosinophilia in pediatric living donor liver transplantation.
    Sanada Y; Ushijima K; Mizuta K; Urahashi T; Ihara Y; Wakiya T; Okada N; Yamada N; Egami S; Hishikawa S; Otomo S; Sakamoto K; Yasuda Y; Kawarasaki H
    Transplant Proc; 2012 Jun; 44(5):1341-5. PubMed ID: 22664012
    [TBL] [Abstract][Full Text] [Related]  

  • 8. c-Kit-positive mast cells in portal tracts cannot be used to distinguish acute cellular rejection from recurrent hepatitis C infection in liver allografts.
    Doria C; di Francesco F; Marino IR; Ramirez CB; Frank A; Iaria M; Galati SA; Farber JL
    Transplant Proc; 2006 Dec; 38(10):3597-600. PubMed ID: 17175342
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The natural history of hepatitis C cirrhosis after liver transplantation.
    Firpi RJ; Clark V; Soldevila-Pico C; Morelli G; Cabrera R; Levy C; Machicao VI; Chaoru C; Nelson DR
    Liver Transpl; 2009 Sep; 15(9):1063-71. PubMed ID: 19718647
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Digital image analysis of liver collagen predicts clinical outcome of recurrent hepatitis C virus 1 year after liver transplantation.
    Manousou P; Dhillon AP; Isgro G; Calvaruso V; Luong TV; Tsochatzis E; Xirouchakis E; Kalambokis G; Cross TJ; Rolando N; O'Beirne J; Patch D; Thornburn D; Burroughs AK
    Liver Transpl; 2011 Feb; 17(2):178-88. PubMed ID: 21280191
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Living donor liver transplantation for end-stage hepatitis C.
    Sugawara Y; Kaneko J; Akamatsu N; Kishi Y; Hata S; Kokudo N; Makuuchi M
    Transplant Proc; 2004 Jun; 36(5):1481-2. PubMed ID: 15251363
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The difference in the fibrosis progression of recurrent hepatitis C after live donor liver transplantation versus deceased donor liver transplantation is attributable to the difference in donor age.
    Selzner N; Girgrah N; Lilly L; Guindi M; Selzner M; Therapondos G; Adeyi O; McGilvray I; Cattral M; Greig PD; Grant D; Levy G; Renner EL
    Liver Transpl; 2008 Dec; 14(12):1778-86. PubMed ID: 19025914
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of AST to platelet ratio index in the detection of liver fibrosis in patients with recurrent hepatitis C after liver transplantation.
    Toniutto P; Fabris C; Bitetto D; Falleti E; Avellini C; Rossi E; Smirne C; Minisini R; Pirisi M
    J Gastroenterol Hepatol; 2007 Nov; 22(11):1904-8. PubMed ID: 17914968
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Living donor liver transplantation in patients with hepatitis C.
    Zimmerman MA; Trotter JF
    Liver Transpl; 2003 Nov; 9(11):S52-7. PubMed ID: 14586896
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of graft size on postoperative thrombocytopenia in living donor liver transplant.
    Marubashi S; Dono K; Miyamoto A; Takeda Y; Nagano H; Umeshita K; Monden M
    Arch Surg; 2007 Nov; 142(11):1054-8. PubMed ID: 18025333
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intra portal donor specific antigen transfusion might prevent re-infection of hepatitis C virus after living related liver transplantation in hepatitis C hepatic cirrhosis.
    Sato Y; Oya H; Yamamoto S; Kobayashi T; Watanabe T; Kokai H; Yamagiwa S; Hatakeyama K
    Hepatogastroenterology; 2009; 56(89):205-7. PubMed ID: 19453058
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Re: Assessment of graft fibrosis by transient elastography in patients with recurrent hepatitis C after living donor liver transplantation.
    Song ZZ
    Transplantation; 2008 Sep; 86(5):749; author reply 749. PubMed ID: 18791461
    [No Abstract]   [Full Text] [Related]  

  • 18. Effect of ischemia-reperfusion on the incidence of acute cellular rejection and timing of histologic hepatitis C virus recurrence after liver transplantation.
    Killackey MT; Gondolesi GE; Liu LU; Paramesh AS; Thung SN; Suriawinata A; Nguyen E; Roayaie S; Schwartz ME; Emre S; Schiano TD
    Transplant Proc; 2008 Jun; 40(5):1504-10. PubMed ID: 18589139
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Early hepatic stellate cell activation is associated with advanced fibrosis after liver transplantation in recipients with hepatitis C.
    Russo MW; Firpi RJ; Nelson DR; Schoonhoven R; Shrestha R; Fried MW
    Liver Transpl; 2005 Oct; 11(10):1235-41. PubMed ID: 16184580
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Elevated blood eosinophil count is a valuable biomarker for predicting late acute cellular rejection after liver transplantation.
    Wang GY; Li H; Liu W; Zhang J; Zhu HB; Wang GS; Zhang Q; Yang Y; Chen GH
    Transplant Proc; 2013 Apr; 45(3):1198-200. PubMed ID: 23622658
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.